Common contraindications cited in the research-use community include: anyone with active or recent cancer (BPC-157 and TB-500 promote angiogenesis), people with Wilson's disease or other copper-metabolism disorders (GHK-Cu component), anyone pregnant or breastfeeding (no safety data), and athletes subject to WADA testing (BPC-157 and TB-500 are prohibited)
Reports often mention reduced muscle tightness, less joint discomfort after high-volume days, and an overall quicker bounce-back between sessions
Reduced Pain and Improved Mobility Pain and discomfort can make regular exercise difficult
Animal studies show that BPC157 accelerates the healing of tendons, ligaments, and the gut lining
The trials used doses of up to 80 milligrams, which is much higher than the typical dose of 100-200 micrograms per day used by people injecting BPC-157, and the peptide did not appear to enter the systemic system when administered rectally 8m5s
Documented interactions with dopaminergic, serotonergic, GABAergic, and prostaglandin systems in animal models